ACHE and Alzheimer disease: These new structures with incorporated 1,2,3-triazolium salts present the new scaffold for drug development as it is known that the current therapy in Alzheimer’s disease (AD) comprises selective AChE inhibitors, while in Parkinson’s and all stages of AD, non-selective inhibitors of ChEs are preferred.